-

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

Contacts

Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

Revvity

NYSE:RVTY
Details
Headquarters: Waltham, Massachusetts
CEO: Prahlad Singh
Employees: 11,000
Organization: PUB

Release Versions

Contacts

Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com

More News From Revvity

Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions that support analytical characterization and molecular design across pharmaceutical and material sciences end markets. This acquisition expands the breadth and depth of Revvity Signals’ solutions for bridging the gap between analytical data and actionable insights, further strengthening its ability to acce...

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: UBS Global Healthcare Conference 2025 Monday, November 10, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Jefferies 2025 London Healthcare Conference Tuesday, November 18, 2025 2:00 p.m. GMT – Max Krakowiak Citi's 2025 Global Healthcare Conference Tuesday, December 2, 2025 9:00 a.m. ET – Prahlad Singh, president and chief execu...

Revvity Announces Financial Results for the Third Quarter of 2025

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 28, 2025. The Company reported GAAP earnings per share of $0.40, as compared to $0.77 in the same period a year ago. Revenue for the quarter was $699 million, as compared to $684 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $82 million, as compared to $98 million for the same period a year ago. GAAP ope...
Back to Newsroom